Jaguar Animal Health, Inc.

JAGX Healthcare Biotechnology

Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024. In the quarter to June 2026, revenue fell 58.9%, EPS grew 95.6%, free cash flow grew 13.8% and total debt fell 83.9%, each against the same quarter a year earlier.

3.53 1.06 −23.09%
Market cap
$8.9M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
3/9
Altman Z
−18.88
Beneish M
−6.24
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 3 4 4
ROE
(538.24%) 729.95% 671.84% (1,125.38%)
ROA
(74.66%) (116.79%) (112.78%) (127.14%)
ROIC
(241.91%) 0.00% 0.00% (28,393.64%)
Return on Tangible Assets
646.03% 269.95% 249.97% 705.52%
Average Days of Receivables
46.58 53.84 3.46 2.60
Free Cash Flow per Share
(9,191.03) (5,396.14) (219.24) (123.80)
Free Cash Flow
(26.65) (23.74) (7.54) (6.68)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026